TY - JOUR
T1 - Modernizing diagnosis of Alzheimer's disease
T2 - A review of global trends and Asia-specific perspectives
AU - Iwatsubo, Takeshi
AU - Sperling, Reisa A.
AU - Algeciras-Schimnich, Alicia
AU - Arai, Hidenori
AU - Barron, Anna M.
AU - Benzinger, Tammie L.S.
AU - Carrillo, Maria C.
AU - Chen, Christopher
AU - Choi, Seong Hye
AU - Fontana, Igor C.
AU - Graff-Radford, Jonathan
AU - Grill, Joshua D.
AU - Heidebrink, Judith
AU - Hu, Chaur Jong
AU - Ihara, Ryoko
AU - Ikeuchi, Takeshi
AU - Iwata, Atsushi
AU - Ip, Fanny C.F.
AU - Fitri, Fasihah Irfani
AU - Jack, Clifford R.
AU - Jeong, Jee Hyang
AU - Jia, Jianping
AU - Kandiah, Nagaendran
AU - Kim, Sang Yun
AU - Kowa, Hisatomo
AU - La Joie, Renaud
AU - Niimi, Yoshiki
AU - Noritake, Ryoji
AU - Okonkwo, Ozioma C.
AU - Palmqvist, Sebastian
AU - Rafii, Michael S.
AU - Raman, Rema
AU - Shen, Yong
AU - Simuni, Tanya
AU - Snyder, Heather M.
AU - Sriwannopas, Orapitchaya
AU - Stoeckel, Luke E.
AU - van der Flier, Wiesje M.
AU - Wang, Huali
AU - Wilcock, Donna M.
AU - Zetterberg, Henrik
AU - Zhou, Jin
AU - Mahinrad, Simin
AU - Sexton, Claire E.
N1 - Publisher Copyright:
© 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2025/8
Y1 - 2025/8
N2 - The landscape of Alzheimer's disease (AD) and related dementias (ADRD) diagnosis is evolving rapidly, driven by advances in disease understanding, biomarker tools, and disease-modifying therapies. Modern diagnostic approaches emphasize biological precision, early detection, and dynamic frameworks that adapt to treatment-induced changes in disease biology. These frameworks enable opportunities for personalized interventions—encompassing pharmacological and non-pharmacological strategies—and for enhanced clinical trial design. However, implementing these advancements globally is influenced by diverse cultural, infrastructural, and regulatory factors. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis, held in Japan, provided a unique platform to explore these global dynamics, particularly from an Asian perspective. This article highlights key discussions from the conference, exploring the role of biomarker-based diagnostic frameworks in shaping the future of AD/ADRD research, diagnosis, and treatment. We highlight regional challenges and successes and emphasize ethical considerations and practical strategies needed to ensure equitable access to diagnostic and therapeutic innovations. Highlights: Advances in biomarkers are reshaping Alzheimer's disease diagnosis and treatment. Modern diagnostic frameworks highlight biological precision, early detection, and dynamic frameworks. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis explored challenges and opportunities in global biomarker implementation. The conference explored geographic-specific impacts, focusing on Asia.
AB - The landscape of Alzheimer's disease (AD) and related dementias (ADRD) diagnosis is evolving rapidly, driven by advances in disease understanding, biomarker tools, and disease-modifying therapies. Modern diagnostic approaches emphasize biological precision, early detection, and dynamic frameworks that adapt to treatment-induced changes in disease biology. These frameworks enable opportunities for personalized interventions—encompassing pharmacological and non-pharmacological strategies—and for enhanced clinical trial design. However, implementing these advancements globally is influenced by diverse cultural, infrastructural, and regulatory factors. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis, held in Japan, provided a unique platform to explore these global dynamics, particularly from an Asian perspective. This article highlights key discussions from the conference, exploring the role of biomarker-based diagnostic frameworks in shaping the future of AD/ADRD research, diagnosis, and treatment. We highlight regional challenges and successes and emphasize ethical considerations and practical strategies needed to ensure equitable access to diagnostic and therapeutic innovations. Highlights: Advances in biomarkers are reshaping Alzheimer's disease diagnosis and treatment. Modern diagnostic frameworks highlight biological precision, early detection, and dynamic frameworks. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis explored challenges and opportunities in global biomarker implementation. The conference explored geographic-specific impacts, focusing on Asia.
KW - Alzheimer's disease
KW - Asia
KW - biomarker
KW - dementia
KW - diagnosis
UR - http://www.scopus.com/inward/record.url?scp=105012409918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105012409918&partnerID=8YFLogxK
U2 - 10.1002/alz.70536
DO - 10.1002/alz.70536
M3 - Review article
AN - SCOPUS:105012409918
SN - 1552-5260
VL - 21
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 8
M1 - e70536
ER -
